Weekly Investment Analysts’ Ratings Updates for vTv Therapeutics (VTVT)

Several brokerages have updated their recommendations and price targets on shares of vTv Therapeutics (NASDAQ: VTVT) in the last few weeks:

• 1/22/2026 – vTv Therapeutics is now covered by analysts at Roth Mkm. They set a “buy” rating and a $58.00 price target on the stock.
• 1/22/2026 – vTv Therapeutics is now covered by analysts at Roth Mkm. They set a “buy” rating and a $58.00 price target on the stock.
• 1/5/2026 – vTv Therapeutics is now covered by analysts at TD Cowen. They set a “buy” rating on the stock.
• 1/5/2026 – vTv Therapeutics is now covered by analysts at TD Cowen. They set a “buy” rating and a $67.00 price target on the stock.
• 12/29/2025 – vTv Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/27/2025 – vTv Therapeutics was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 12/22/2025 – vTv Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – vTv Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock, up previously from $36.00.
• 12/15/2025 – vTv Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – vTv Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – vTv Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.